Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib Skin Toxicity Dosing in Head and Neck Cancer
NCT00519077Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Mar 2005
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by University of Chicago. Started Mar 2005; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00519077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00519077.